Essential thrombocytosis attributed to JAK2-T875N germline mutation

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Essential thrombocytosis (ET) is a myeloproliferative neoplasm characterized by increased platelet counts.
• The Janus kinase 2 (JAK2) gene is frequently mutated in ET, with the V617F mutation being the most common.
• Understanding novel mutations in JAK2 is crucial for diagnosing and treating ET.

Observation:

• Exome sequencing identified a non-canonical JAK2 mutation, JAK2-T875N, in a patient with ET and a family history of thrombocytosis.
• Sanger sequencing confirmed the presence of the JAK2-T875N variant.
• The patient's family history included suspected ET and cerebral infarction.

Findings:

• JAK2-T875N mutation was evaluated in cell lines, demonstrating increased JAK2 activity.
• Transfected cells showed elevated levels of phosphorylated JAK2 and Erk (extracellular signal-regulated kinase).
• Enhanced STAT3 and STAT5 activation and increased cellular growth without interleukin-3 (IL-3) stimulation were observed in JAK2-T875N-mutated cells.

Implications:

• This study reports the first case of ET associated with the JAK2-T875N mutation.
• The findings suggest that JAK2-T875N is a functional mutation contributing to ET pathogenesis.
• Further research into this mutation may reveal new therapeutic targets for ET and related myeloproliferative neoplasms.